Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study

To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients...

Descripción completa

Detalles Bibliográficos
Autores: Corominas, Héctor, Alegre, Cayetano, Narváez García, Francisco Javier, Fernández-Cid, Carlos Marras, Torrente Segarra, Vicenç, Gómez Rodríguez, Manuel, Maceiras Pan, Francisco, Morlà, Rosa, Martínez Rodríguez, Fernando José, Gómez-Centeno, Antoni, Losada Ares, Laura, Gonzalez Molina, Rocío, Paredes González-Albo, Silvia, Dalmau-Carolà, Joan, Pérez-García, Carolina, Barbazán Álvarez, Ceferino, Ercole, Liliana, Terrancle, Maria Ángeles, ACT-AXIS Study Group.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/162720
Acceso en línea:https://hdl.handle.net/2445/162720
Access Level:acceso abierto
Palabra clave:Fatiga
Artritis reumatoide
Farmacologia
Fatigue
Rheumatoid arthritis
Pharmacology
Descripción
Sumario:To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 ± 1.0 at baseline to 2.7 ± 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 ± 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients.

Similares en LA Referencia